


## Amendments To The Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

### In the Claims:

What is claimed is:

1. (Currently amended) A compound of formula (I):



wherein:

R<sup>1</sup> represents phenyl ~~which may be~~ optionally substituted by one or more substituents which may be the same or different and which are selected from the group consisting of: halogen; trifluoromethyl; -C<sub>1-6</sub>alkyl optionally substituted by COOR<sup>15</sup>; -C<sub>1-6</sub>alkoxy optionally substituted by COOR<sup>15</sup>; hydroxy; oxo; cyano; -C<sub>1-6</sub>alkyl-cyano; C<sub>2-6</sub> alkenyl ~~C<sub>4-6</sub>alkenyl~~ optionally substituted by COOR<sup>15</sup>; C<sub>3-7</sub>cycloalkyl; C<sub>1-6</sub>alkylsulfonyl; C<sub>2-6</sub> alkenoxy ~~C<sub>4-6</sub>alkenoxyl~~; C<sub>1-6</sub>alkylthio; NR<sup>15</sup>R<sup>16</sup>; -C<sub>1-6</sub>alkyl-aryl; aryl; -CO-aryl optionally substituted by halogen; -CO-heteroaryl; -CO-heterocyclyl; -COOR<sup>15</sup>; -COR<sup>15</sup>; -CONR<sup>15</sup>R<sup>16</sup> ~~optionally substituted by C<sub>4-6</sub>alkyl, halogen or C<sub>4-6</sub>alkylC<sub>4-6</sub>alkoxy~~; and -C<sub>1-6</sub>alkyl-CO-aryl groups; and in which

R<sup>15</sup> and R<sup>16</sup> independently represent hydrogen, C<sub>1-6</sub>alkyl or C<sub>3-8</sub>cycloalkyl or together may be fused to form a 5- to 7-membered non-aromatic heterocyclic ring optionally interrupted by an O or S atom and optionally substituted by a halogen, C<sub>1-6</sub>alkyl or C<sub>1-6</sub>alkylC<sub>1-6</sub>alkoxy group;


Z represents CO;

r is 0;

p is 1;

m is 0;

R<sup>3</sup> represents a group of formula (i):



wherein

f is 0;

g is 2;

h is 1;

k is 0; and

R<sup>13</sup> represents C<sub>1-6</sub>alkyl or C<sub>3-8</sub>cycloalkyl;

or a pharmaceutically acceptable salt thereof.

2-11. (Cancelled)

Add the following new claims:

12. (Currently amended) A compound according to claim 1 wherein R<sup>1</sup> is phenyl ~~which may be~~ optionally substituted by 1, 2 or 3 substituents which may be the same or different and which are selected from the group consisting of: chlorine, fluorine, bromine; trifluoromethyl; methyl, ethyl, isopropyl, propyl, t-butyl (optionally substituted by COOH, COOMe or COOEt); methoxy, butoxy, -OCH(Me)<sub>2</sub>, -OC(Me)<sub>3</sub> (optionally substituted by COOH or COOMe); hydroxy; oxo; cyano; -CH<sub>2</sub>-CN; ethenyl (optionally substituted by COOMe); cyclopentyl; -SO<sub>2</sub>Me; -OCH<sub>2</sub>CH=CH<sub>2</sub>; -S-ethyl; N(Me)<sub>2</sub>; benzyl; phenyl; -CO-phenyl (optionally substituted by chlorine); -CO-azetidiny; -CO-tetrahydropyranyl; COOH, COOMe, COOt-butyl; -CO-methyl, -CO-ethyl, -CO-isopropyl, -CO-cyclopropyl, -CO-cyclobutyl, -CO-cyclopentyl, -CO-cyclohexyl; -CONH<sub>2</sub>, -CO-pyrrolidiny, -CO-morpholiny, -CO-piperaziny, -CO-piperidiny, -CO-thiomorpholiny (optionally substituted by methyl, fluorine and -CH<sub>2</sub>OMe); or -CH<sub>2</sub>COphenyl groups; or a pharmaceutically acceptable salt thereof.

13. (Previously presented) A compound according to claim 1 wherein R<sup>1</sup> is phenyl substituted by C<sub>1-6</sub>alkylsulfonyl.

14. (Previously presented) A compound according to claim 1 wherein R<sup>1</sup> is phenyl substituted by SO<sub>2</sub>Me.

15. (Previously presented) A compound according to claim 1 wherein R<sup>1</sup> is phenyl substituted by SO<sub>2</sub>Me at the para position.

16. (Previously presented) A compound according to claim 1 wherein -O-R<sup>3</sup> is present at the para position of the phenyl group with respect to the rest of the compound.

17. (Previously presented) A compound according to claim 1 wherein R<sup>13</sup> represents isopropyl, cyclopropyl or cyclobutyl.

18. (Previously presented) A compound according to claim 13, wherein R<sup>13</sup> represents isopropyl, cyclopropyl or cyclobutyl.

19. (Previously presented) A compound according to claim 14, wherein R<sup>13</sup> represents isopropyl, cyclopropyl or cyclobutyl.

20. (Previously presented) A compound which is 1-(4-{[1-(1-methylethyl)-4-piperidinyl]oxy}phenyl)-4-{[4-(methylsulfonyl)phenyl]carbonyl}piperazine or a pharmaceutically acceptable salt thereof.

21. (Previously presented) A pharmaceutical composition which comprises a compound of formula (I) as defined in claim 1 or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier or excipient.

22. (Currently amended) A method of treatment of diseases of the upper respiratory tract which comprises administering to a human host—in need thereof an effective amount of a compound of formula (I) as defined in claims 1 or a pharmaceutically acceptable salt thereof.

23. (Previously presented) A method of treatment according to claim 21 in which the disease is allergic rhinitis.

24. (Previously presented) A pharmaceutical composition which comprises a compound of formula (I) as defined in claim 18 or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier or excipient.

25. (Currently amended) A method of treatment of diseases of the upper respiratory tract which comprises administering to a human ~~host~~ in need thereof an effective amount of a compound of formula (I) as defined in claims 18 or a pharmaceutically acceptable salt thereof.

26. (Previously presented) A method of treatment according to claim 25 in which the disease is allergic rhinitis.

27. (Previously presented) A pharmaceutical composition which comprises a compound of formula (I) as defined in claim 19 or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier or excipient.

28. (Currently amended) A method of treatment of diseases of the upper respiratory tract which comprises administering to a human ~~host~~—in need thereof an effective amount of a compound of formula (I) as defined in claims 19 or a pharmaceutically acceptable salt thereof.

29. (Previously presented) A method of treatment according to claim 28 in which the disease is allergic rhinitis.